SVCM

Saturn V Capital Management Portfolio holdings

AUM $456M
1-Year Est. Return 177.94%
This Quarter Est. Return
1 Year Est. Return
+177.94%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$456M
AUM Growth
+$209M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
26
New
Increased
Reduced
Closed

Top Buys

1
+$22.1M
2
+$18.3M
3
+$15.4M
4
ABVX
Abivax
ABVX
+$15.2M
5
MNPR icon
Monopar Therapeutics
MNPR
+$12.7M

Top Sells

1
+$35.2M
2
+$13.7M
3
+$7.31M
4
ASND icon
Ascendis Pharma
ASND
+$6.59M
5
ARGX icon
argenx
ARGX
+$5.67M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$8.95B
$68M 14.92%
801,224
+178,745
AMLX icon
2
Amylyx Pharmaceuticals
AMLX
$1.51B
$62.6M 13.72%
4,604,878
+1,344,308
JAZZ icon
3
Jazz Pharmaceuticals
JAZZ
$10.1B
$39.6M 8.69%
300,610
+93,658
DYN icon
4
Dyne Therapeutics
DYN
$2.86B
$33.8M 7.42%
2,674,469
+1,219,040
COGT icon
5
Cogent Biosciences
COGT
$5.98B
$29.1M 6.38%
2,025,041
-272,483
PCVX icon
6
Vaxcyte
PCVX
$5.85B
$28.4M 6.23%
788,441
+244,220
CELC icon
7
Celcuity
CELC
$4.51B
$23.4M 5.13%
473,828
-711,692
CGON icon
8
CG Oncology
CGON
$3.34B
$23.4M 5.12%
579,895
-6,752
IRON icon
9
Disc Medicine
IRON
$3.39B
$22.5M 4.94%
340,897
-55,218
PHVS icon
10
Pharvaris
PHVS
$1.57B
$22.1M 4.85%
+886,332
XENE icon
11
Xenon Pharmaceuticals
XENE
$3.31B
$20.2M 4.44%
503,701
+35,337
CNTA
12
Centessa Pharmaceuticals
CNTA
$4.21B
$17.8M 3.91%
734,539
-58,788
MRUS icon
13
Merus
MRUS
$7.28B
$17.3M 3.8%
184,135
-40,125
LENZ
14
LENZ Therapeutics
LENZ
$855M
$17.1M 3.76%
368,176
+25,864
OCUL icon
15
Ocular Therapeutix
OCUL
$2.4B
$13.5M 2.95%
1,151,686
+423,110
MNPR icon
16
Monopar Therapeutics
MNPR
$507M
$12.7M 2.78%
+155,370
NAMS icon
17
NewAmsterdam Pharma
NAMS
$4.35B
$4.36M 0.96%
153,147
-67,548
SNDX icon
18
Syndax Pharmaceuticals
SNDX
$1.63B
– –
-500,551
CTNM
19
Contineum Therapeutics
CTNM
$306M
– –
-319,348
ARGX icon
20
argenx
ARGX
$56.4B
– –
-10,285
ASND icon
21
Ascendis Pharma
ASND
$12.4B
– –
-38,191
KALV icon
22
KalVista Pharmaceuticals
KALV
$683M
– –
-62,793
MLTX icon
23
MoonLake Immunotherapeutics
MLTX
$887M
– –
-290,784
NBIX icon
24
Neurocrine Biosciences
NBIX
$15.2B
– –
-58,181
REPL icon
25
Replimune Group
REPL
$784M
– –
-128,917
1
2